Inhibition of JAK/STAT and BCL2 signaling by ruxolitinib and venetoclax reduces tumor burden in an AML xenograft mouse model. Twenty-four NSG mice engrafted with luciferase expressing MOLM-13 cells were treated with vehicle, venetoclax (25 mg/kg, intraperitoneally), ruxolitinib (50 mg/kg, by mouth), or both for 3 weeks. (A) Each row represents an individual mouse from each treatment group. Bioluminescence images shown before the start of the treatment, each week of the treatment period, and 1 week after the end of the treatment. (B) Mean bioluminescence of all mice in each treatment group (n = 6 for each group) recorded before the start of the treatment, during the 3-week treatment period, and 1 week after the end of the treatment. Error bars represent standard error of the mean. Statistically significant difference is represented by asterisk, which signify **P < .01 by Mann-Whitney test.